FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Mechanism of an integrated PBL-KAP-AI spiral health education model for breast cancer patients. PMID 41404555 · Front Public Health · 2025 The study is a randomized trial in oncology (breast cancer) with original results. However, it is excluded because it is not a Phase III/IIIb or Phase II/III trial (phase is not specified and cannot be inferred), it does not involve a drug-containing intervention (it evaluates a health education model), and its primary outcomes (health behaviors, beliefs, quality of life) are not time-to-event endpoints (OS, PFS, DFS, etc.) with Kaplan-Meier or HR analysis. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Dosimetry-guided peptide receptor radionuclide therapy in neuroendocrine tumors: interim safety analysis of the DUONEN trial. PMID 41404513 · Front Endocrinol (Lausanne) · 2025 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| Effect of preoperative oral carbohydrate combined with postoperative early enteral nutrition on the perioperative rehabilitation of patients with colorectal cancer: a multicenter randomized controlled trial. PMID 41393952 · Front Nutr · 2025 The study is a randomized trial in colorectal cancer patients. It reports on perioperative recovery outcomes (e.g., time to first exhaust, hospitalization length) but does not report on a time-to-event efficacy endpoint such as OS, PFS, DFS, or Kaplan-Meier survival analysis. The intervention (preoperative oral carbohydrates and postoperative early enteral nutrition) is non-drug, not a therapeutic anti-neoplastic drug. The trial phase is not specified in the record. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Effects of Different Doses of Butorphanol on Perioperative Analgesia, Recovery, and Immune Function in Patients Undergoing Cytoreductive Surgery for Ovarian Cancer: A Randomized Controlled Trial. PMID 41393328 · Drug Des Devel Ther · 2025 The study is a randomized trial of a drug for perioperative pain management in ovarian cancer surgery, but it does not meet key eligibility criteria: it is not a Phase III/IIIb or Phase II/III trial, and it lacks a time-to-event oncology efficacy endpoint (e.g., OS, PFS). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Association Between Cytomegalovirus Viremia Clearance and Post-Solid Organ Transplant Mortality in Patients With Refractory Cytomegalovirus Infection: SOLSTICE Post Hoc Analysis. PMID 41384277 · Transpl Int · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Phase II Trial of an Orelabrutinib-Based Combination Therapy in Newly Diagnosed Primary Central Nervous System Lymphoma. PMID 41383547 · Blood Lymphat Cancer · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Phase 1, randomized, crossover study comparing intravenous GTX-104 to oral nimodipine in healthy human subjects. PMID 41359540 · PLoS One · 2025 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Ivarmacitinib reduces the need for adding/escalating medications in moderate-to-severe rheumatoid arthritis patients: a post hoc analysis from a phase III trial. PMID 41357893 · Front Pharmacol · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| First-line immunochemotherapy for advanced NSCLC in Asian patients: a meta-analysis of phase 3 RCTs. PMID 41347089 · Front Oncol · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Research trends in neoadjuvant therapy for esophageal cancer: a bibliometric and meta-analysis. PMID 41346615 · Front Immunol · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Sequential HIPEC, Claudin18.2-targeted therapy, and CapeOx chemotherapy leading to resolution of peritoneal metastases and curative resection in gastric cancer: a case report and literature review. PMID 41341578 · Front Immunol · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Comparison of Atezolizumab plus Aevacizumab and Atezolizumab plus Aabozantinib for advanced hepatocellular carcinoma: A cost-effectiveness analysis. PMID 41335584 · PLoS One · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A phase II clinical trial of Bifidobacterium longum subsp. longum BL21 for preventing acute radiation enteritis among pelvic radiotherapy patients. PMID 41293184 · Front Nutr · 2025 The study is a phase II, single-arm, non-randomized trial evaluating a probiotic for toxicity prevention, lacking the required phase, randomization, drug intervention, and time-to-event efficacy endpoint. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Prophylactic effect of the traditional Chinese medicine formula danxiong granules (TDX105) on hand-foot skin reaction associated with the antitumor targeted drug regorafenib: a randomized, double-blind, placebo-controlled trial. PMID 41282614 · Front Pharmacol · 2025 The record does not provide explicit evidence that the trial is Phase III/IIIb or Phase II/III, which is a required criterion for eligibility. Furthermore, the primary endpoint is not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). Although PFS is reported, its status as a primary or key secondary endpoint is not confirmed. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The effects of Growth hormone treatment discontinuation in Adults on Metabolic profile, Body composition and quality Of Life (GAMBOL Study). PMID 41262296 · NIHR Open Res · 2025 未发现恶性肿瘤人群证据。 |
H
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Study Protocol of SURVIVE HERoes (NCT06643585): Trastuzumab Deruxtecan for molecular relapse in HER2+/ Low early breast cancer with ctDNA positivity after primary therapy. PMID 41259337 · PLoS One · 2025 方案论文未报告临床试验结果。 |
H
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Nurse led telephonic palliative care versus specialty outpatient palliative care: pragmatic, randomised clinical trial. PMID 41245582 · BMJ Med · 2025 The study is a randomized clinical trial with oncology patients (advanced cancer) and reports primary results, but it is ineligible because it lacks a drug-containing intervention (interventions are palliative care delivery models) and does not report a time-to-event efficacy endpoint. The primary outcome is change in quality of life (FACT-G score), not a time-to-event endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The effectiveness of kinesiology taping on dysphagia in brain tumor survivors after neurosurgery: study protocol for a pilot randomized controlled trial. PMID 41244764 · Front Med (Lausanne) · 2025 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| International cost-effectiveness analysis in osimertinib after chemoradiotherapy in stage III EGFR-mutated non-small cell lung cancer. PMID 41235190 · Front Public Health · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Closed-loop temperature management with internet of things technology support in elderly laparoscopic rectal cancer surgery: A randomised controlled trial. PMID 41231776 · PLoS One · 2025 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Is radioiodine necessary for patients with low-risk differentiated thyroid cancer after thyroidectomy: a pooled analysis of ESTIMABL2 and IoN trials. PMID 41229489 · Front Oncol · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety analysis of treatment in patients with EGFR-mutated advanced NSCLC who progressed on TKIs: a systematic review and meta-analysis. PMID 41229435 · Front Immunol · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Immune checkpoint inhibitors for extensive-stage small-cell lung cancer: a network meta-analysis and cost-effectiveness analysis. PMID 41221276 · Front Immunol · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Ursodeoxycholic acid treatment of LPAC presenting as post cholecystectomy pain: rationale and design of a randomised trial. PMID 41216274 · Transl Gastroenterol Hepatol · 2025 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Obesity Management in Adults With and Without Type 2 Diabetes: A Systematic Review. PMID 41211586 · J Obes · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Design of debunking the frailty-sarcopenia-ADT axis in metastatic prostate cancer with multicomponent exercise: the FIERCE trial protocol. PMID 41210271 · Front Sports Act Living · 2025 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Comparative risk of uveitis with Janus kinase inhibitors versus tumor necrosis factor inhibitors in ankylosing spondylitis and psoriatic diseases: a target trial emulation study. PMID 41208989 · Front Immunol · 2025 The study is a non-oncology, non-randomized observational cohort study comparing the risk of uveitis in patients with spondyloarthritis and psoriatic diseases treated with Janus kinase inhibitors versus tumor necrosis factor inhibitors. While it includes drug interventions and a time-to-event endpoint, it does not meet the core oncology or randomized trial criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The efficacy, safety, and pharmacokinetics/pharmacodynamics of telitacicept following efgartigimod in generalized myasthenia gravis: protocol of a randomized controlled trial. PMID 41200184 · Front Immunol · 2025 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Ethical issues in a cluster randomised controlled trial for evaluating effectiveness of screening for breast cancer by clinical breast examination in India. PMID 41195487 · Indian J Med Ethics · 2025 The record is an ethical analysis of a cluster randomized screening trial, not a report of a drug-containing oncology Phase III/IIIb or Phase II/III randomized trial with a primary/key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effects of Continuous Perioperative Esketamine Infusion on Postoperative Depression in Breast Cancer Patients: A Randomized Controlled Double-Blind Trial. PMID 41185705 · Drug Des Devel Ther · 2025 The study is a randomized, controlled trial in breast cancer patients investigating a drug intervention (esketamine) for postoperative depression. However, it is not explicitly a Phase III or definitive randomized trial as required, and the primary efficacy endpoint is a depression score (HAMD-17), not a time-to-event oncology endpoint like overall survival or progression-free survival. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Sorafenib Combined with Tislelizumab and Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: A Phase II Study. PMID 41179951 · Immunotargets Ther · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Antibody-drug conjugates versus docetaxel for previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled trials. PMID 41179119 · Ther Adv Med Oncol · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Optimistic Bias and Personality Factors in Adherence to Oral Anticancer Treatments in Metastatic Breast Cancer: A Retrospective Analysis of Data From a Randomized Controlled Trial. PMID 41172984 · Cancer Control · 2025 The study is a secondary analysis of an RCT focusing on adherence and psychological factors, not the original trial report. It does not report on a primary or key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| First-line immune checkpoint inhibitors plus targeted therapy versus sorafenib or lenvatinib monotherapy for unresectable or advanced hepatocellular carcinoma: a meta-analysis of phase 3 trials. PMID 41169385 · Front Immunol · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Cost-effectiveness of cadonilimab plus chemotherapy vs chemotherapy alone for advanced gastric cancer: evidence to inform drug pricing in the U.S. and China. PMID 41164188 · Front Immunol · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Antibody-drug conjugates targeting the cadherin, claudin and nectin families of adhesion molecules. PMID 41164107 · Front Mol Med · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Expert Opinion Report on the Challenges in the Management of Psoriatic Arthritis in United Arab Emirates: A Focus on Interleukin-17 Inhibitors. PMID 41158207 · Open Access Rheumatol · 2025 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Transcutaneous Auricular Vagus Nerve Stimulation for Prevention of Postoperative Delirium in Older Adults Undergoing Total Knee Arthroplasty: A Multicenter Randomized Controlled Trial Protocol. PMID 41146865 · Clin Interv Aging · 2025 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Antibody response to tetanus, diphtheria, poliomyelitis, hepatitis B, and H. influenzae b vaccines in allogeneic hematopoietic stem cell transplant adult recipients: A multicenter trial. PMID 41144397 · PLoS One · 2025 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| On-treatment modified Glasgow Prognostic Score (mGPS) in hepatocellular carcinoma treated with atezolizumab and bevacizumab provides prognostic information. PMID 41142780 · Front Immunol · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Cost-effectiveness analysis of cabozantinib plus atezolizumab for advanced hepatocellular carcinoma. PMID 41142252 · Front Pharmacol · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effect of Baofukang suppository on the relative indexes of epithelial mesenchymal transformation of tumor cells and prognosis in patients with cervical cancer. PMID 41139264 · Pak J Pharm Sci · 2025 The record describes a randomized trial in cervical cancer patients with a drug-containing intervention, but the abstract reports only surrogate/biomarker outcomes (EMT markers, cytokines, immune cells) and safety. It does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS) or Kaplan-Meier/HR analysis. The phase is not explicitly stated. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinoma. PMID 41122636 · Front Oncol · 2025 The report presents pre-specified secondary endpoints of health-related quality of life (PROs) from a phase 3 randomized trial, but does not include primary or key secondary time-to-event efficacy endpoints such as OS, PFS, or DFS. The analysis is focused on patient-reported outcomes, which are excluded from the cohort criteria. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Metronomic chemotherapy of paclitaxel plus cisplatin in patients with metastatic breast cancer: a target trial emulation study. PMID 41122314 · Ther Adv Med Oncol · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Outcomes of endoscopic third ventriculostomy in comparison to ventriculoperitoneal shunt in obstructive hydrocephalus - A randomized controlled trial. PMID 41112363 · Surg Neurol Int · 2025 The study is not oncology-focused (obstructive hydrocephalus) and lacks a drug-containing intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Baseline CD4+/CD8+ TEMRA Levels and Early Response Predict Survival After Umbilical Cord-Derived Mesenchymal Stem Cells Infusion in Acute GVHD Patients: A Randomized Double-Blinded Placebo-Controlled Multicentre Clinical Trial. PMID 41084724 · J Blood Med · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Prevalence of Molecular Markers of Resistance to Antimalarial Drugs Three Years After Perennial Malaria Chemoprevention in Sierra Leone. PMID 41080970 · Gates Open Res · 2025 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Metformin and estrogen modulation in LABC with T2DM: A 36-month randomized trial. PMID 41079227 · Open Med (Wars) · 2025 The study is a randomized drug trial in human oncology with time-to-event endpoints and original results. However, it is not eligible because the trial phase is not established as Phase III/IIIb or Phase II/III (a required criterion), and the design is not a standard definitive randomized controlled trial as per the criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Protection From SARS-CoV-2 Infection With an Oral Nosode (BiosimCovex): A Randomized, Double-Blind, Placebo-Controlled, Phase III Study. PMID 41064737 · Glob Adv Integr Med Health · 2025 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy of hybrid remote neuropsychological rehabilitation on cognitive complaints in post-therapeutic lower-grade glioma: the FREEDOME randomized study protocol. PMID 41064168 · Front Psychol · 2025 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |